Browse drugs

…rgoing percutaneous coronary intervention (PCI), ticagrelor and prasugrel are established potent P2Y12 inhibitors. Selection between thes…

…cagrelor, P=1) and postoperative sICH (0.6% clopidogrel vs 0.6% ticagrelor, P=1). Functional outcomes, aneurysm occlusion at discharge, an…

…tenosis rates were lower with ticagrelor (5% vs 21%).Conclusion Ticagrelor 60 mg for DAPT in intracranial stenting is safe and effective. …

…morrhagic events in the ticagrelor group and 35 (27.56%) in the clopidogrel group, (P=0.889).Conclusion Half-dose ticagrelor was effective …

…label aspirin for days 2–7. Both groups will receive open-label aspirin (100 mg daily) for days 8–90.Study outcomes The primary efficac…

…nt CAS between January 2016 and August 2025 and received either ticagrelor or clopidogrel. Primary outcomes at 180 days included ischemic …

…ed with increased thromboembolic risk following flow diversion. Ticagrelor use was not associated with reduced thromboembolic complication…

…40, using clopidogrel), the LOF-Clopidogrel group (n=309, using clopidogrel), and the LOF-Ticagrelor group (n=105, using ticagrelor). The p…

… P2Y12 receptor antagonist), mainly with low-dose prasugrel and ticagrelor. Off-label low-dose antiplatelet agents significantly reduced m…

…ity in reducing the incidence of stent thrombosis compared with clopidogrel. Despite this, ticagrelor has been shown to have side effects n…

…ar aneurysm (4x4mm).After a 5-day DAPT regimen with Aspirin and Ticagrelor, the right carotid cave aneurysm was treated with a flow-divert…

…tment platelet reactivity to prasugrel, even after doubling the prasugrel dose. This case highlights rare resistance to newer P2Y12 inhib…